Drug Type Gene therapy |
Synonyms NGN-103 |
Target |
Mechanism CLN5 stimulants(Ceroid-lipofuscinosis neuronal protein 5 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Neurogene, Inc. (New York)Startup |
Active Organization- |
Inactive Organization Neurogene, Inc. (New York)Startup |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuronal Ceroid-Lipofuscinoses | Preclinical | US | Neurogene, Inc. (New York)Startup | - |